Evidence map›Paper›PMID 25179587›Full record

Trial reportContemporary clinical trials2014

Achieving cannabis cessation -- evaluating N-acetylcysteine treatment (ACCENT): design and implementation of a multi-site, randomized controlled study in the National Institute on Drug Abuse Clinical Trials Network.

Erin A McClure, Susan C Sonne, Theresa Winhusen, Kathleen M Carroll, Udi E Ghitza, Aimee L McRae-Clark, Abigail G Matthews, Gaurav Sharma, Paul Van Veldhuisen, Ryan G Vandrey and 10 more

Registry-linked trialAbstract readMulticenter StudyRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Contemporary clinical trials, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01675661 (Achieving Cannabis Cessation), which is not on this map. Cited by 30 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
30citing papers in PubMed, 2 pooled it
5.8field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT01675661 phase3completednot on this map

Achieving Cannabis Cessation: Evaluating N-Acetylcysteine Treatment (ACCENT)

TypeinterventionalSponsorMedical University of South CarolinaRan2014 to 2015Enrolled302ConditionsCannabis DependenceArmsN-Acetylcysteine, Placebo
3 · Its place in the literature

Who cites it

30 citing papers in PubMed, 2 syntheses or guidelines pooled it, 50 citations in OpenAlex.

  1. Pharmacotherapies for cannabis use disorder.The Cochrane database of systematic reviews · 2025
    Pooled it
  2. Pharmacotherapies for cannabis dependence.The Cochrane database of systematic reviews · 2019
    Pooled it
  3. Trial
  4. Evaluating cannabis use risk reduction as an alternative clinical outcome for cannabis use disorder.Psychology of addictive behaviors : journal of the Society of Psychologists in Addictive Behaviors · 2022
    Trial
  5. Characterizing cannabis use reduction and change in functioning during treatment: Initial steps on the path to new clinical endpoints.Psychology of addictive behaviors : journal of the Society of Psychologists in Addictive Behaviors · 2022
    Trial
  6. Trial
  7. Trial
  8. Trial
  9. Trial
  10. Trial
  11. Trial
  12. Trial
  13. Trial
  14. Trial
  15. Trial
  16. Trial
  17. Article
  18. Article
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors at 9 institutions in 1 country.

Erin A McClureMedical University of South Carolina College of Medicine, 67 President St., Charleston, SC 29425, United States. Electronic address: mccluree@musc.edu.
Susan C SonneMedical University of South Carolina College of Medicine, 67 President St., Charleston, SC 29425, United States.
Theresa WinhusenAddiction Sciences Division, Department of Psychiatry and Behavioral Neuroscience, University of Cincinnati College of Medicine, 3131 Harvey Avenue, Cincinnati, OH 45229, United States.
Kathleen M CarrollYale University School of Medicine, 950 Campbell Ave, West Haven, CT 06516, United States.
Udi E GhitzaCenter for the Clinical Trials Network, National Institute on Drug Abuse, 6001 Executive Boulevard, MSC 9557, Bethesda, MD 20892, United States.
Aimee L McRae-ClarkMedical University of South Carolina College of Medicine, 67 President St., Charleston, SC 29425, United States.
Abigail G MatthewsThe EMMES Corporation, 401 N. Washington St., Rockville, MD 20850, United States.
Gaurav SharmaThe EMMES Corporation, 401 N. Washington St., Rockville, MD 20850, United States.
Paul Van VeldhuisenThe EMMES Corporation, 401 N. Washington St., Rockville, MD 20850, United States.
Ryan G VandreyJohns Hopkins University, School of Medicine, 5510 Nathan Shock Dr., Baltimore, MD 21224, United States.
Frances R LevinColumbia University/New York State Psychiatric Institute, 1051 Riverside Drive, New York, NY 10032, United States.
Roger D WeissDivision of Alcohol and Drug Abuse, McLean Hospital, 115 Mill St., Belmont, MA 02478, United States; Department of Psychiatry, Harvard Medical School, 25 Shattuck St., Boston, MA 02115, United States.
Robert LindbladThe EMMES Corporation, 401 N. Washington St., Rockville, MD 20850, United States.
Colleen AllenThe EMMES Corporation, 401 N. Washington St., Rockville, MD 20850, United States.
Larissa J MooneyUniversity of California, Los Angeles, David Geffen School of Medicine, 1640 S. Sepulveda Blvd., Suite 120, Los Angeles, CA 90025, United States.
Louise HaynesMedical University of South Carolina College of Medicine, 67 President St., Charleston, SC 29425, United States.
Gregory S BrighamAddiction Sciences Division, Department of Psychiatry and Behavioral Neuroscience, University of Cincinnati College of Medicine, 3131 Harvey Avenue, Cincinnati, OH 45229, United States.
Steve SparenborgCenter for the Clinical Trials Network, National Institute on Drug Abuse, 6001 Executive Boulevard, MSC 9557, Bethesda, MD 20892, United States.
Albert L HassonUniversity of California, Los Angeles, David Geffen School of Medicine, 1640 S. Sepulveda Blvd., Suite 120, Los Angeles, CA 90025, United States.
Kevin M GrayMedical University of South Carolina College of Medicine, 67 President St., Charleston, SC 29425, United States.
Emmes (United States) · USMedical University of South Carolina · USNational Institute on Drug Abuse · USUniversity of California, Los Angeles · USUniversity of Cincinnati Medical Center · USColumbia University · USJohns Hopkins University · USLemuel Shattuck Hospital · USYale University · US

Funding

The National Drug Abuse Treatment Clinical Trials NetworkU10DA013045 · NIDA · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI LING, WALTER NMN · 1999 to 2015
$52.6M
Clinical Trials Network, Ohio Valley Node U10DA013732U10DA013732 · NIDA · UNIVERSITY OF CINCINNATI · PI WINHUSEN, T JOHN · 2000 to 2015
$45.0M
Southern Consortium Node of the Clinical Trials NetworkU10DA013727 · NIDA · MEDICAL UNIVERSITY OF SOUTH CAROLINA · PI BRADY, KATHLEEN T. · 2000 to 2015
$34.4M
The National Drug Abuse Treatment Clinical Trials Network (U10)U10DA015831 · NIDA · MC LEAN HOSPITAL (BELMONT, MA) · PI CARROLL, KATHLEEN M., WEISS, ROGER D. · 2002 to 2015
$28.8M
CLINICAL TRIALS NETWORK: PACIFIC NORTHWEST NODEU10DA013714 · NIDA · UNIVERSITY OF WASHINGTON · PI DONOVAN, DENNIS MICHAEL, ROLL, JOHN M. · 2001 to 2015
$25.5M
Western States Node of the National Drug Abuse Treatment Clinical Trials NetworkU10DA015815 · NIDA · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI MCCARTY, DENNIS, SORENSEN, JAMES L · 2002 to 2015
$25.2M
CLINICAL TRIALS NETWORK MID-ATLANTIC COLLABORATIVE GROUPU10DA013034 · NIDA · JOHNS HOPKINS UNIVERSITY · PI SCHWARTZ, ROBERT P, STITZER, MAXINE L · 1999 to 2015
$25.2M
Western States Node of the National Drug Abuse Treatment Clinical Trials Network (TMS for CUD) UG1DA015815 · NIDA · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Keith N. Humphreys, Philip Todd Korthuis · 2015 to 2026
$24.6M
CLINICAL TRIALS NETWORK: NEW ENGLAND NODEU10DA013038 · NIDA · YALE UNIVERSITY · PI CARROLL, KATHLEEN M. · 1999 to 2010
$17.3M
A Randomized Controlled Trial of Varenicline for Adolescent Smoking CessationU01DA031779 · NIDA · MEDICAL UNIVERSITY OF SOUTH CAROLINA · PI GRAY, KEVIN M · 2012 to 2016
$3.3M
Substance Abuse Treatment Development and Clinical Research MentoringK24DA029647 · NIDA · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI LEVIN, FRANCES RUDNICK · 2010 to 2019
$1.8M
Mentoring in Drug Abuse and Dual Diagnosis ResearchK24DA022288 · NIDA · MCLEAN HOSPITAL · PI WEISS, ROGER D. · 2007 to 2016
$1.8M
NIDA NIH HHS K01 DA036739NIDA NIH HHS K24 DA022288NIDA NIH HHS K24DA022288NIDA NIH HHS K24 DA029647NIDA NIH HHS N01DA102221NIDA NIH HHS N01DA92217NIDA NIH HHS U01 DA031779NIDA NIH HHS U10 DA013034NIDA NIH HHS U10DA013034NIDA NIH HHS U10 DA013038NIDA NIH HHS U10 DA013045NIDA NIH HHS U10DA013045NIDA NIH HHS U10 DA013714NIDA NIH HHS U10DA013714NIDA NIH HHS U10 DA013727NIDA NIH HHS U10DA013727NIDA NIH HHS U10 DA013732NIDA NIH HHS U10DA013732NIDA NIH HHS U10 DA015815NIDA NIH HHS U10 DA015831NIDA NIH HHS U10DA15831NIDA NIH HHS UG1 DA015815
6 · The paper itself

Abstract

Despite recent advances in behavioral interventions for cannabis use disorders, effect sizes remain modest, and few individuals achieve long-term abstinence. One strategy to enhance outcomes is the addition of pharmacotherapy to complement behavioral treatment, but to date no efficacious medications targeting cannabis use disorders in adults through large, randomized controlled trials have been identified. The National Institute on Drug Abuse Clinical Trials Network (NIDA CTN) is currently conducting a study to test the efficacy of N-acetylcysteine (NAC) versus placebo (PBO), added to contingency management, for cannabis cessation in adults (ages 18-50). This study was designed to replicate positive findings from a study in cannabis-dependent adolescents that found greater odds of abstinence with NAC compared to PBO. This paper describes the design and implementation of an ongoing 12-week, intent-to-treat, double-blind, randomized, placebo-controlled study with one follow-up visit four weeks post-treatment. Approximately 300 treatment-seeking cannabis-dependent adults will be randomized to NAC or PBO across six study sites in the United States. The primary objective of this 12-week study is to evaluate the efficacy of twice-daily orally-administered NAC (1200 mg) versus matched PBO, added to contingency management, on cannabis abstinence. NAC is among the first medications to demonstrate increased odds of abstinence in a randomized controlled study among cannabis users in any age group. The current study will assess the cannabis cessation efficacy of NAC combined with a behavioral intervention in adults, providing a novel and timely contribution to the evidence base for the treatment of cannabis use disorders.

Indexed as

Research DesignAcetylcysteineAdolescentAdultDouble-Blind MethodFemaleGenetic TestingHumansMaleMarijuana AbuseMiddle AgedNational Institute on Drug Abuse (U.S.)SmokingUnited StatesYoung AdultAcetylcysteineCannabisClinical study designMarijuanaN-acetylcysteinePharmacotherapyRandomized trials

Identifiers

PMID25179587
PMCPMC4252394
OpenAlexW2001253512

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.